Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers

被引：9

作者：

Berl, Tomas ^{[1
]}

机构：

[1] Univ Colorado Hlth Sci, Div Nephrol, Denver, CO 80262 USA

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2008年 / 23卷 / 08期

关键词：

D O I：

10.1093/ndt/gfn239

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

引用

收藏

页码：2443 / 2447

页数：5

相关论文

共 26 条

[21] Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
Rossing, K
Schjoedt, KJ
Jensen, BR
Boomsma, F
Parving, HH
[J]. KIDNEY INTERNATIONAL, 2005, 68 (03) : 1190 - 1198
[22] Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy - A double-blind randomized cross-over study
Rossing, K
Christensen, PK
Hansen, BV
Carstensen, B
Parving, HH
[J]. DIABETES CARE, 2003, 26 (01) : 150 - 155
[23] Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies
Ruggenenti, P
Mise, N
Pisoni, R
Arnoldi, F
Pezzotta, A
Perna, A
Cattaneo, D
Remuzzi, G
[J]. CIRCULATION, 2003, 107 (04) : 586 - 592
[24] SCHJOEDT KJ, 2007, P EUR ASS STUD DIAB
[25] Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study
Schmieder, RE
Klingbeil, AU
Fleischmann, EH
Veelken, R
Delles, C
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (10): : 3038 - 3045
[26] Telmisartan, ramipril, or both in patients at high risk for vascular events
Yusuf, Salim
Teo, Koon K.
Pogue, Janice
Dyal, Leanne
Copland, Ingrid
Schumacher, Helmut
Ingelheim, Boehringer
Dagenais, Gilles
Sleight, Peter
Anderson, Craig
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (15) : 1547 - 1559